These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

650 related items for PubMed ID: 29978469

  • 21. Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia.
    Evangelisti C, Chiarini F, Cappellini A, Paganelli F, Fini M, Santi S, Martelli AM, Neri LM, Evangelisti C.
    J Cell Physiol; 2020 Jun; 235(6):5413-5428. PubMed ID: 31904116
    [Abstract] [Full Text] [Related]

  • 22. Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway.
    Chen Z, Wang C, Dong H, Wang X, Gao F, Zhang S, Zhang X.
    Mol Med; 2020 Jan 30; 26(1):14. PubMed ID: 32000660
    [Abstract] [Full Text] [Related]

  • 23. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
    García-García C, Rivas MA, Ibrahim YH, Calvo MT, Gris-Oliver A, Rodríguez O, Grueso J, Antón P, Guzmán M, Aura C, Nuciforo P, Jessen K, Argilés G, Dienstmann R, Bertotti A, Trusolino L, Matito J, Vivancos A, Chicote I, Palmer HG, Tabernero J, Scaltriti M, Baselga J, Serra V.
    Clin Cancer Res; 2015 Dec 15; 21(24):5499-5510. PubMed ID: 26272063
    [Abstract] [Full Text] [Related]

  • 24. mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer.
    Mashima T, Taneda Y, Jang MK, Mizutani A, Muramatsu Y, Yoshida H, Sato A, Tanaka N, Sugimoto Y, Seimiya H.
    Oncotarget; 2017 Jul 18; 8(29):47902-47915. PubMed ID: 28615517
    [Abstract] [Full Text] [Related]

  • 25. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
    Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, Ribero D, Muratore A, Massucco P, Pisacane A, Risio M, Capussotti L, Marsoni S, Di Nicolantonio F, Bardelli A, Comoglio PM, Trusolino L, Bertotti A.
    Clin Cancer Res; 2012 May 01; 18(9):2515-25. PubMed ID: 22392911
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
    Tran KB, Kolekar S, Jabed A, Jaynes P, Shih JH, Wang Q, Flanagan JU, Rewcastle GW, Baguley BC, Shepherd PR.
    BMC Cancer; 2021 Feb 06; 21(1):136. PubMed ID: 33549048
    [Abstract] [Full Text] [Related]

  • 29. MiR-452 promotes an aggressive colorectal cancer phenotype by regulating a Wnt/β-catenin positive feedback loop.
    Li T, Jian X, He H, Lai Q, Li X, Deng D, Liu T, Zhu J, Jiao H, Ye Y, Wang S, Yang M, Zheng L, Zhou W, Ding Y.
    J Exp Clin Cancer Res; 2018 Sep 25; 37(1):238. PubMed ID: 30253791
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
    Penna I, Molla A, Grazia G, Cleris L, Nicolini G, Perrone F, Picciani B, Del Vecchio M, de Braud F, Mortarini R, Anichini A.
    Oncotarget; 2016 Jan 26; 7(4):3947-65. PubMed ID: 26678033
    [Abstract] [Full Text] [Related]

  • 32. Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.
    Wang Z, Kang B, Gao Q, Huang L, Di J, Fan Y, Yu J, Jiang B, Gao F, Wang D, Sun H, Gu Y, Li J, Su X.
    Cancer Sci; 2021 Sep 26; 112(9):3895-3910. PubMed ID: 34185934
    [Abstract] [Full Text] [Related]

  • 33. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
    Coussy F, El Botty R, Lavigne M, Gu C, Fuhrmann L, Briaux A, de Koning L, Dahmani A, Montaudon E, Morisset L, Huguet L, Sourd L, Painsec P, Chateau-Joubert S, Larcher T, Vacher S, Melaabi S, Salomon AV, Marangoni E, Bieche I.
    J Hematol Oncol; 2020 Feb 22; 13(1):13. PubMed ID: 32087759
    [Abstract] [Full Text] [Related]

  • 34. The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases.
    Ippen FM, Alvarez-Breckenridge CA, Kuter BM, Fink AL, Bihun IV, Lastrapes M, Penson T, Schmidt SP, Wojtkiewicz GR, Ning J, Subramanian M, Giobbie-Hurder A, Martinez-Lage M, Carter SL, Cahill DP, Wakimoto H, Brastianos PK.
    Clin Cancer Res; 2019 Jun 01; 25(11):3374-3383. PubMed ID: 30796030
    [Abstract] [Full Text] [Related]

  • 35. TRIB3 Interacts With β-Catenin and TCF4 to Increase Stem Cell Features of Colorectal Cancer Stem Cells and Tumorigenesis.
    Hua F, Shang S, Yang YW, Zhang HZ, Xu TL, Yu JJ, Zhou DD, Cui B, Li K, Lv XX, Zhang XW, Liu SS, Yu JM, Wang F, Zhang C, Huang B, Hu ZW.
    Gastroenterology; 2019 Feb 01; 156(3):708-721.e15. PubMed ID: 30365932
    [Abstract] [Full Text] [Related]

  • 36. Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer.
    Lee CL, Cremona M, Farrelly A, Workman JA, Kennedy S, Aslam R, Carr A, Madden S, O'Neill B, Hennessy BT, Toomey S.
    Cancer Biol Ther; 2023 Dec 31; 24(1):2223388. PubMed ID: 37326340
    [Abstract] [Full Text] [Related]

  • 37. APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells.
    Chen M, Mashima T, Oishi T, Muramatsu Y, Seto Y, Takamatsu M, Kawata N, Morino S, Nakamura A, Inaba S, Yuan X, Maruyama K, Suzuki M, Sato A, Yoshida H, Jang MK, Mizutani A, Takeuchi K, Yamaguchi K, Shirai F, Nagayama S, Katayama R, Seimiya H.
    Br J Cancer; 2024 Jan 31; 130(1):151-162. PubMed ID: 37968472
    [Abstract] [Full Text] [Related]

  • 38. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.
    Yuan J, Mehta PP, Yin MJ, Sun S, Zou A, Chen J, Rafidi K, Feng Z, Nickel J, Engebretsen J, Hallin J, Blasina A, Zhang E, Nguyen L, Sun M, Vogt PK, McHarg A, Cheng H, Christensen JG, Kan JL, Bagrodia S.
    Mol Cancer Ther; 2011 Nov 31; 10(11):2189-99. PubMed ID: 21750219
    [Abstract] [Full Text] [Related]

  • 39. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
    Bradford LS, Rauh-Hain A, Clark RM, Groeneweg JW, Zhang L, Borger D, Zukerberg LR, Growdon WB, Foster R, Rueda BR.
    Gynecol Oncol; 2014 May 31; 133(2):346-52. PubMed ID: 24561032
    [Abstract] [Full Text] [Related]

  • 40. Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma.
    Makinoshima H, Umemura S, Suzuki A, Nakanishi H, Maruyama A, Udagawa H, Mimaki S, Matsumoto S, Niho S, Ishii G, Tsuboi M, Ochiai A, Esumi H, Sasaki T, Goto K, Tsuchihara K.
    Cancer Res; 2018 May 01; 78(9):2179-2190. PubMed ID: 29490947
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.